<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548212" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548212/" /><meta name="ncbi_pagename" content="Alemtuzumab - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Alemtuzumab - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Alemtuzumab" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/04/14" /><meta name="citation_pmid" content="31643537" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548212/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Alemtuzumab" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/04/14" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548212/" /><meta name="description" content="Alemtuzumab is a recombinant human monoclonal antibody to human CD52 which is used in the therapy of chronic lymphocytic leukemia, in induction regimens for solid organ transplantation and for resistant forms of relapsing multiple sclerosis. Alemtuzumab has not been linked to serum aminotransferase elevations during therapy but has been implicated in rare cases of clinically apparent liver injury as well as reactivation of chronic hepatitis B and exacerbations of chronic hepatitis C that can be severe and even fatal." /><meta name="og:title" content="Alemtuzumab" /><meta name="og:type" content="book" /><meta name="og:description" content="Alemtuzumab is a recombinant human monoclonal antibody to human CD52 which is used in the therapy of chronic lymphocytic leukemia, in induction regimens for solid organ transplantation and for resistant forms of relapsing multiple sclerosis. Alemtuzumab has not been linked to serum aminotransferase elevations during therapy but has been implicated in rare cases of clinically apparent liver injury as well as reactivation of chronic hepatitis B and exacerbations of chronic hepatitis C that can be severe and even fatal." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548212/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Alemtuzumab/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548212/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D1A31046640E10000000003C30104.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548212_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548212_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Alefacept/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Alfuzosin/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548212_"><span class="title" itemprop="name">Alemtuzumab</span></h1><p class="small">Last Update: <span itemprop="dateModified">April 14, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Alemtuzumab.OVERVIEW"><h2 id="_Alemtuzumab_OVERVIEW_">OVERVIEW</h2><div id="Alemtuzumab.Introduction"><h3>Introduction</h3><p>Alemtuzumab is a recombinant human monoclonal antibody to human CD52 which is used in the therapy of chronic lymphocytic leukemia, in induction regimens for solid organ transplantation and for resistant forms of relapsing multiple sclerosis. Alemtuzumab has not been linked to serum aminotransferase elevations during therapy but has been implicated in rare cases of clinically apparent liver injury as well as reactivation of chronic hepatitis B and exacerbations of chronic hepatitis C that can be severe and even fatal.</p></div><div id="Alemtuzumab.Background"><h3>Background</h3><p>Alemtuzumab (al&#x0201d; em tooz&#x02019; ue mab) is a recombinant, human IgG1 kappa monoclonal antibody which is directed at and binds avidly to the human cell surface marker CD52 which is present on T and B cells, monocytes, macrophages and other bone marrow cells. Alemtuzumab therapy leads to depletion of lymphocytes with suppression of B cells for 6 to 12 months and T cells for 12 to 24 months. Alemtuzumab was approved in the United States in 2004 for use in chronic lymphocytic leukemia (CLL). It has also been used extensively off-label as a part of induction therapy for prevention of rejection after solid organ transplantation and treatment of several autoimmune diseases. In 2017, indications were extended to include resistant relapsing multiple sclerosis. Alemtuzumab is available in single use vials of 30 mg/mL under the brand name Campath for CLL and Lemtrada for multiple sclerosis. The typical dose and regimen varies with indication. Alemtuzumab has significant adverse side effects, largely due to the profound immunosuppression. Common adverse events include epistaxis, headache, hypertension, rhinitis, dry skin, back pain, excessive bleeding and skin rash. Uncommon, but serious complications include severe infusions reactions, cytopenias (including fatal autoimmune anemia and thrombocytopenia), autoimmune reconstitution syndromes (including Graves disease, autoimmune thrombocytopenia, sarcoidosis and Goodpasture syndrome) and opportunistic infections.</p></div><div id="Alemtuzumab.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In large clinical trials, alemtuzumab therapy has been associated with a high rate of side effects including serious infusion reactions, infections and bone marrow suppression, but hepatotoxicity and serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations were usually not mentioned in the many clinical trials of its use. Strikingly, however, trials of alemtuzumab in multiple sclerosis reported high rates of autoimmune disease arising 6 to 18 months after a cycle of infusions. The autoimmune conditions were usually Graves disease, reported in 20% to 30% of patients who were followed long term after treatment with alemtuzumab. Less commonly reported were autoimmune thrombocytopenia and Goodpasture syndrome, which like Graves disease are considered due to B-cell autoimmunity. Less common have been single reported examples of autoimmune hepatitis arising after alemtuzumab therapy of multiple sclerosis. Complicating this association, however, is the fact that autoimmune hepatitis is not uncommon in patients with multiple sclerosis independent of treatment. Nevertheless, idiosyncratic liver disease with autoimmune features has been reported often enough for it to be listed as a warning on product labels for alemtuzumab.</p><p>In addition, alemtuzumab is a potent immunosuppressive agent and predisposes to opportunistic bacterial, viral, fungal and viral infections including reactivation of hepatitis B and C. Several instances of reactivation of hepatitis B have been reported in patients with HBsAg in serum who were treated with this monoclonal antibody. In addition, some patients with anti-HBc without HBsAg in serum have developed HBV reactivation with reappearance of HBsAg (reverse seroconversion) after alemtuzumab therapy. These episodes can be severe and fatal instances have been reported. Finally, exacerbation and possibly reactivation of hepatitis C has been described in patients receiving alemtuzumab therapy.</p><p>Likelihood score: C (probable rare cause of clinically apparent liver injury).</p></div><div id="Alemtuzumab.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>Alemtuzumab is a monoclonal antibody and, while metabolized in the liver, is metabolized to small peptides and amino acids that are not likely to be immunogenic or toxic. The immunosuppression caused by alemtuzumab, on the other hand, may cause reactivation of hepatitis B and exacerbations of chronic hepatitis C. Furthermore, withdrawal of alemtuzumab and reconstitution of the immune system may account for the rare instance of an autoimmune hepatitis as B and T cell function begins to return 6 to 18 months after the monoclonal antibody infusion.</p></div><div id="Alemtuzumab.Outcome_and_Management"><h3>Outcome and Management</h3><p>Alemtuzumab appears to have little intrinsic hepatotoxicity and idiosyncratic liver injury must be very rare, if it occurs at all. In contrast, alemtuzumab is capable of causing reconstitution autoimmune reactions as well as reactivation of hepatitis B and worsening of hepatitis C. For these reasons, it is appropriate to screen patients for hepatitis B and C infection before starting therapy, and providing prophylaxis or treatment of these viral infections before or concurrent with starting monoclonal antibody therapy.</p><p>Drug Class: <a href="/books/n/livertox/AntineoplasticAgents/">Antineoplastic Agents</a>, <a href="/books/n/livertox/MonoclonalAntibodies/">Monoclonal Antibodies</a>; <a href="/books/n/livertox/Transplant_Drugs/">Transplant Agents</a>; <a href="/books/n/livertox/MultipleSclerosisAge/">Multiple Sclerosis Agents</a></p><p>Other Drugs in the Subclass, Transplant Agents, Monoclonal Antibodies: <a href="/books/n/livertox/Basiliximab/">Basiliximab</a>, <a href="/books/n/livertox/Daclizumab/">Daclizumab</a>, <a href="/books/n/livertox/Muromonab-CD3/">Muromonab</a></p></div></div><div id="Alemtuzumab.PRODUCT_INFORMATION"><h2 id="_Alemtuzumab_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Alemtuzumab &#x02013; Campath&#x000ae;, Lemtrada&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antineoplastic Agents, Monoclonal Antibodies</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?label=all&#x00026;query=Alemtuzumab" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Alemtuzumab.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Alemtuzumab_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Alemtuzumab.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548212/table/Alemtuzumab.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Alemtuzumab.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Alemtuzumab.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Alemtuzumab.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_Alemtuzumab.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Alemtuzumab.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Alemtuzumab.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Alemtuzumab</td><td headers="hd_h_Alemtuzumab.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135330159" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">216503-57-0</a></td><td headers="hd_h_Alemtuzumab.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Monoclonal Antibody</td><td headers="hd_h_Alemtuzumab.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not Available</td></tr></tbody></table></div></div></div><div id="Alemtuzumab.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Alemtuzumab_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 14 April 2020</p><p>Abbreviations: CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Alemtuzumab.REF.zimmerman.1999">Zimmerman HJ. Drugs used to treat rheumatic and musculospastic disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 517-54.<div><i>(Expert review of hepatotoxicity published in 1999, well before the availability of most monoclonal antibody therapies).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.reuben.2011">Reuben A. Hepatotoxicity of immunosuppressive drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2011, pp. 569-91.<div><i>(Review of hepatotoxicity of immunosuppressive agents, mentions that "the biological immunosuppressants are largely free from hepatotoxicity, with the exception of the TNF alpha antagonists"; no specific discussion of alemtuzumab).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.wellstein.2018">Wellstein A, Giaccone G, Atkins MB, Sausville EA. Pathway-targeted therapies: monoclonal antibodies, protein kinase inhibitors, and various small molecules. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1203-36.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.coles.1999.1691">Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, Weetman A, et al.  Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. <span><span class="ref-journal">Lancet. </span>1999;<span class="ref-vol">354</span>(9191):1691–5.</span> [<a href="/pubmed/10568572" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10568572</span></a>]<div><i>(Among 27 patients with multiple sclerosis given a 5 day course of alemtuzumab and followed for 18 months, 9 [33%] developed Graves disease [2 with ophthalmopathy] and antibodies to thyrotropin receptor, an autoimmune response not seen with alemtuzumab therapy of other conditions including rheumatoid arthritis).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.rai.2002.3891">Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Sant&#x000e1;barbara P, et al.  Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. <span><span class="ref-journal">J Clin Oncol. </span>2002;<span class="ref-vol">20</span>:3891–7.</span> [<a href="/pubmed/12228210" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12228210</span></a>]<div><i>(Among 24 patients with resistant CLL treated with alemtuzumab, all [100%] developed infusion reactions and ten [41%] severe, opportunistic infections including 4 with pneumocystis jiroveci pneumonia; no mention of ALT elevations, hepatitis or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.marcos.2004.966">Marcos A, Eghtesad B, Fung JJ, Fontes P, Patel K, Devera M, Marsh W, et al.  Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. <span><span class="ref-journal">Transplantation. </span>2004;<span class="ref-vol">78</span>:966–71.</span> [<a href="/pmc/articles/PMC2993510/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2993510</span></a>] [<a href="/pubmed/15480160" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15480160</span></a>]<div><i>(Among 76 adults undergoing liver transplantation who received induction therapy with alemtuzumab, subsequent rates of rejection, graft loss, death and adverse reactions were similar to a cohort of 84 contemporaneous transplant recipients; no mention of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.tzakis.2004.1209">Tzakis AG, Tryphonopoulos P, Kato T, Nishida S, Levi DM, Madariaga JR, Gaynor JJ, et al.  Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. <span><span class="ref-journal">Transplantation. </span>2004;<span class="ref-vol">77</span>:1209–14.</span> [<a href="/pubmed/15114087" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15114087</span></a>]<div><i>(Among 40 adults undergoing liver transplantation who received induction therapy with alemtuzumab and low dose tacrolimus, subsequent rates of graft loss, death and adverse reactions were similar to a cohort of 50 contemporaneous transplant recipients given conventional immunosuppressive therapy; routine liver test results were similar between the two groups).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.heider.2004.64">Heider U, Fleissner C, Zavrski I, Jakob C, Dietzel T, Eucker J, Ockenga J, et al.  Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection. <span><span class="ref-journal">Eur J Haematol. </span>2004;<span class="ref-vol">72</span>:64–6.</span> [<a href="/pubmed/14962266" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14962266</span></a>]<div><i>(69 year old man with CLL and anti-HBc without HBsAg in serum developed reactivation of hepatitis B after chemotherapy with CHOP, rituximab and fludarabine that responded to lamivudine therapy and did not worsen when he was subsequently treated with alemtuzumab).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.iannitto.2005.254">Iannitto E, Minardi V, Calvaruso G, Mul&#x000e8; A, Ammatuna E, Di Trapani R, Ferraro D, et al.  Hepatitis B virus reactivation and alemtuzumab therapy. <span><span class="ref-journal">Eur J Haematol. </span>2005;<span class="ref-vol">74</span>:254–8.</span> [<a href="/pubmed/15693796" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15693796</span></a>]<div><i>(Two patients with CLL with anti-HBc without HBsAg in serum developed reactivation of hepatitis B with alemtuzumab therapy, one 4 weeks after starting and one 5 months after alemtuzumab treatment and two months after withdrawal of lamivudine prophylaxis; both recovered with antiviral therapy).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.cortelezzi.2006.467">Cortelezzi A, Vigan&#x000f2; M, Zilioli VR, Fantini NN, Pasquini MC, Deliliers GL, Colombo M, et al.  Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. <span><span class="ref-journal">J Clin Virol. </span>2006;<span class="ref-vol">35</span>:467–9.</span> [<a href="/pubmed/16316778" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16316778</span></a>]<div><i>(49 year old man with CLL and anti-HBc without HBsAg in serum developed severe reactivation of HBV after treatment with high doses of chlorambucil, responding to lamivudine and adefovir therapy, and without rise in HBV DNA levels during subsequent rescue therapy with alemtuzumab).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.moses.2006.1560">Moses SE, Lim ZY, Sudhanva M, Devereux S, Ho AY, Pagliuca A, Zuckerman M, et al.  Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. <span><span class="ref-journal">J Med Virol. </span>2006;<span class="ref-vol">78</span>:1560–3.</span> [<a href="/pubmed/17063522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17063522</span></a>]<div><i>(Among 8 alemtuzumab treated bone marrow transplant recipients who had anti-HBc without HBsAg in serum, reactivation occurred in 1 of 2 patients who did not receive prophylaxis, but in none of 6 who did receive prophylactic lamivudine).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.fiegl.2006.2408">Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, Haslbauer F, et al. Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia.  Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. <span><span class="ref-journal">Cancer. </span>2006;<span class="ref-vol">107</span>:2408–16.</span> [<a href="/pubmed/17054106" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17054106</span></a>]<div><i>(Retrospective analysis of results of alemtuzumab therapy in 115 patients with CLL reported side effects of severe infections in 51%, severe neutropenia in 26%, and severe hypersensitivity reactions in 8%, but did not mention ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.magliocca.2006.705">Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab(Campath-1H) for immunosuppressive therapy in organ transplantation. <span><span class="ref-journal">Transpl Int. </span>2006;<span class="ref-vol">19</span>:705–14.</span> [<a href="/pubmed/16918530" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16918530</span></a>]<div><i>(Review of efficacy of alemtuzumab in various forms of organ transplantation; no discussion of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.james.2007.29">James DF, Kipps TJ. Alemtuzumab in chronic lymphocytic leukemia. <span><span class="ref-journal">Future Oncol. </span>2007;<span class="ref-vol">3</span>:29–42.</span> [<a href="/pubmed/17280499" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17280499</span></a>]<div><i>(Review of history of development, clinical efficacy and toxicity of alemtuzumab as therapy of CLL, no mention of hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.hillmen.2007.5616">Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C, et al.  Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. <span><span class="ref-journal">J Clin Oncol. </span>2007;<span class="ref-vol">25</span>:5616–23.</span> [<a href="/pubmed/17984186" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17984186</span></a>]<div><i>(Among 297 patients with chronic lymphocytic leukemia treated with alemtuzumab or chlorambucil, adverse events included infusion reactions, cytomegalovirus [CMV] infections, anemia and neutropenia; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.demko.2008.167">Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: Alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. <span><span class="ref-journal">Oncologist. </span>2008;<span class="ref-vol">13</span>:167–74.</span> [<a href="/pubmed/18305062" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18305062</span></a>]<div><i>(Independent FDA review of studies in support of alemtuzumab as therapy of chronic lymphocytic leukemia listed common side effects including infusion reactions [87%], CMV viremia [56%], neutropenia [14%] and anemia [13%]; no mention of hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.hui.2008.1">Hui CK, Cheung WW, Leung KW, Cheng VC, Tang BS, Li IW, Luk JM, et al.  Retracted: outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen. <span><span class="ref-journal">Hepatology. </span>2008;<span class="ref-vol">48</span>:1–10.</span> [<a href="/pubmed/18452145" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18452145</span></a>]<div><i>(Among 21 patients with HBV DNA without HBsAg in serum [17 with anti-HBc] treated with alemtuzumab chemotherapy, 6 developed reactivation of hepatitis B with reappearance of HBsAg in all and rise in liver enzymes in 5, despite early intervention with lamivudine therapy; this article was later retracted).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF18">Alemtuzumab (Campath) off-label for relapsing multiple sclerosis. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2009;<span class="ref-vol">51</span>(1307):17–8.</span> [<a href="/pubmed/19265776" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19265776</span></a>]<div><i>(Discussion of the off-label use of alemtuzumab for relapsing multiple sclerosis mentions that side effects include infusion reactions, autoimmune thyroid disorders and thrombocytopenic purpura, but does not mention ALT elevations or clinically apparent hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.dhesi.2009.245">Dhesi S, Boland B, Colquhoun S. Alemtuzumab and liver transplantation: a review. <span><span class="ref-journal">Curr Opin Organ Transplant. </span>2009;<span class="ref-vol">14</span>:245–9.</span> [<a href="/pubmed/19417659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19417659</span></a>]<div><i>(Short review of induction therapy using alemtuzumab in preparation of liver transplantation summarizing results from two US studies suggesting lower rates of rejection and ability to use lower doses of maintenance therapy).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.jones.2009.2052">Jones JL, Phuah CL, Cox AL, Thompson SA, Ban M, Shawcross J, Walton A, et al.  IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). <span><span class="ref-journal">J Clin Invest. </span>2009;<span class="ref-vol">119</span>:2052–61.</span> [<a href="/pmc/articles/PMC2701868/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2701868</span></a>] [<a href="/pubmed/19546505" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19546505</span></a>]<div><i>(Analysis of lymphocyte function in patients with multiple sclerosis who develop reconstitution autoimmunity suggest that lymphocytes that proliferate after ablation by alemtuzumab are skewed towards self-reactivity and susceptible to apoptosis features that are promoted by high levels of IL21).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.cai.2010.1511">Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. <span><span class="ref-journal">Transplantation. </span>2010;<span class="ref-vol">90</span>:1511–5.</span> [<a href="/pubmed/21057388" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21057388</span></a>]<div><i>(Since 2003, most solid organ transplant recipients have received induction therapy and analyses of the UNOS registry for this period shows highest rates of patient and graft survival with alemtuzumab [89% 5 year patient survival] as compared to antithymocyte globulin [89%], basiliximab [84%], daclizumab [77%], steroids [75%], or no induction [71%]).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.anoop.2010.484">Anoop P, Wotherspoon A, Matutes E. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia. <span><span class="ref-journal">Br J Haematol. </span>2010;<span class="ref-vol">148</span>:484–6.</span> [<a href="/pubmed/19874308" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19874308</span></a>]<div><i>(39 year old man with CLL had anti-HCV and normal ALT levels without HCV RNA in serum, but developed high levels of HCV RNA and ALT levels 34 days after starting weekly infusions of alemtuzumab and prednisone, not having had reactivation during rituximab or previous fludarabine and prednisone therapy).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.hanaway.2011.1909">Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, Croy R, et al. INTAC Study Group.  Alemtuzumab induction in renal transplantation. <span><span class="ref-journal">N Engl J Med. </span>2011;<span class="ref-vol">364</span>:1909–19.</span> [<a href="/pubmed/21591943" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21591943</span></a>]<div><i>(Among 474 patients undergoing renal transplantation and given alemtuzumab or convention induction therapy, acute rejection rates during the first 3 years were lower with alemtuzumab than basiliximab in low risk patients [15% vs 24%], but were similar with alemtuzumab and antithymocyte globulin in high risk patients [30% vs 24%]).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.kim.2012.1515">Kim SJ, Moon JH, Kim H, Kim JS, Hwang YY, Intragumtornchai T, Issaragrisil S, et al.  Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group. <span><span class="ref-journal">Leuk Lymphoma. </span>2012;<span class="ref-vol">53</span>:1515–24.</span> [<a href="/pubmed/22273250" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22273250</span></a>]<div><i>(Retrospective analysis of infectious complications among 182 patients treated with alemtuzumab between 2003-2009 in 6 Asian countries identified 66 cases of CMV, 25 varicella-zoster virus, 31 fungal infections, 4 pneumocystis jirovecii pneumonia, HBV reactivation 4 [in previously HBsAg negative patients], and tuberculosis 16).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.coles.2012.1829">Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, et al.  CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. <span><span class="ref-journal">Lancet. </span>2012;<span class="ref-vol">380</span>(9856):1829–39.</span> [<a href="/pubmed/23122650" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23122650</span></a>]<div><i>(Among 798 patients with relapsing remitting multiple sclerosis treated with alemtuzumab [12 or 24 mg for 5 and 3 days at month 0 and 12] or interferon beta-1a [44 mcg three times weekly], relapse rates were lower with alemtuzumab [35% vs 53%] and adverse event rates were slightly higher [77% vs 69%], particularly for autoimmune thyroid abnormalities [16% and 19% vs 5%] and autoimmune thrombocytopenia [1% vs none]; while liver toxicity was reported in 3-4% vs 6%], details of which were not provide).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.costelloe.2012.335">Costelloe L, Jones J, Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. <span><span class="ref-journal">Expert Rev Neurother. </span>2012;<span class="ref-vol">12</span>:335–41.</span> [<a href="/pubmed/22364332" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22364332</span></a>]<div><i>(Review of the secondary autoimmune conditions associated with alemtuzumab therapy of multiple sclerosis including Graves disease in 12-33% of subjects, thrombocytopenic purpura in 1-3% and Goodpasture&#x02019;s syndrome in &#x0003c;1%).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.putra.2014.827">Putra J, Suriawinata AA. Adenovirus hepatitis presenting as tumoral lesions in an immunocompromised patient. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:827–9.</span> [<a href="/pubmed/25332270" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25332270</span></a>]<div><i>(59 year old man with T-cell leukemia treated with alemtuzumab developed fever and adenovirus hepatitis, responding to cidofovir therapy).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.di_bisceglie.2015.703">Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? <span><span class="ref-journal">Hepatology. </span>2015;<span class="ref-vol">61</span>:703–11.</span> [<a href="/pmc/articles/PMC5497492/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5497492</span></a>] [<a href="/pubmed/25412906" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25412906</span></a>]<div><i>(Review of the pathogenesis, clinical course, treatment and prevention of HBV reactivation in patients receiving immunosuppressive or anticancer therapies, with particular focus on rituximab and ofatumumab).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.baker.2017.961">Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. <span><span class="ref-journal">JAMA Neurol. </span>2017;<span class="ref-vol">74</span>:961–9.</span> [<a href="/pmc/articles/PMC5710323/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5710323</span></a>] [<a href="/pubmed/28604916" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28604916</span></a>]<div><i>(Analysis of depletion and reconstitution of B and T cell subsets after alemtuzumab therapy suggests that the secondary autoimmunity is due to rebound in autoreactive B cells with relative deficiency in T cell regulatory function).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.willis.2018.1779">Willis MD, Hope-Gill B, Flood-Page P, Joseph F, Needham E, Jones J, Coles A, Robertson NP. Sarcoidosis following alemtuzumab treatment for multiple sclerosis. <span><span class="ref-journal">Mult Scler. </span>2018;<span class="ref-vol">24</span>:1779–82.</span> [<a href="/pubmed/30307364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30307364</span></a>]<div><i>(Among 187 patients with multiple sclerosis treated with alemtuzumab, 3 developed sarcoidosis, 2 to 4 years after the last infusion).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.el_sankari.2018.331">El Sankari S, Dahlqvist G, Monino L, van Pesch V. Auto-immune hepatitis in a patient with multiple sclerosis treated with alemtuzumab. <span><span class="ref-journal">Acta Neurol Belg. </span>2018;<span class="ref-vol">118</span>:331–3.</span> [<a href="/pubmed/29713905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29713905</span></a>]<div><i>(25 year old woman with multiple sclerosis developed Graves disease 11 months after a second course of alemtuzumab and liver injury 1 month after starting thiamazole for the hyperthyroidism [bilirubin 14 times ULN, ALT 5 times ULN], not responding to stopping antithyroid drug but improving with prednisone therapy).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.holm_y.2019.497">Holm&#x000f8;y T, Fevang B, Olsen DB, Spigset O, B&#x000f8; L. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. <span><span class="ref-journal">BMC Res Notes. </span>2019;<span class="ref-vol">12</span>:497.</span> [<a href="/pmc/articles/PMC6689881/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6689881</span></a>] [<a href="/pubmed/31405369" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31405369</span></a>]<div><i>(Systematic review of the literature and of adverse event databases identified 9 cases of alemtuzumab-attributed severe adverse events leading to death, including 1 case of autoimmune hepatitis arising a year after therapy; no further details given).</i></div></div></li><li><div class="bk_ref" id="Alemtuzumab.REF.beattie.2019.158">Beattie W, Yan B, Sood S. Acute severe hepatitis with alemtuzumab and rechallenge after a year. <span><span class="ref-journal">J Clin Neurosci. </span>2019;<span class="ref-vol">60</span>:158–60.</span> [<a href="/pubmed/30348589" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30348589</span></a>]<div><i>(49 year old woman with relapsing remitting multiple sclerosis developed test abnormalities within 2 days of starting alemtuzumab and methylprednisolone [bilirubin 0.7 mg/dL, ALT 378 rising to 577 U/L, Alk P 87], which resolved within 4 weeks and had recurrence with a second course 12 months later [bilirubin normal, ALT 400 rising to 700] again resolving within 4 weeks).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548212</span><span class="label">PMID: <a href="/pubmed/31643537" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643537</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Alefacept/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Alfuzosin/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548212&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548212/?report=reader">PubReader</a></li><li><a href="/books/NBK548212/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548212" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548212" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Alemtuzumab. [Updated 2020 Apr 14].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548212/pdf/Bookshelf_NBK548212.pdf">PDF version of this page</a> (110K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Alemtuzumab+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Alemtuzumab: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Alemtuzumab" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Alemtuzumab: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4868066" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4868066" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4868066" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12512923" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.</a><span class="source">[Med Oncol. 2002]</span><div class="brieflinkpop offscreen_noflow">Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Cavalli-Björkman N, Osby E, Lundin J, Kalin M, Osterborg A, Gruber A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Med Oncol. 2002; 19(4):277-80. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27925187" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.</a><span class="source">[Immunology. 2017]</span><div class="brieflinkpop offscreen_noflow">Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">von Kutzleben S, Pryce G, Giovannoni G, Baker D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Immunology. 2017 Apr; 150(4):444-455. Epub 2017 Jan 3.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27560943" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.</a><span class="source">[PLoS One. 2016]</span><div class="brieflinkpop offscreen_noflow">CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hotta R, Ohira M, Matsuura T, Muraoka I, Tryphonopoulos P, Fan J, Tekin A, Selvaggi G, Levi D, Ruiz P, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PLoS One. 2016; 11(8):e0161618. Epub 2016 Aug 25.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27082500" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alemtuzumab for multiple sclerosis.</a><span class="source">[Cochrane Database Syst Rev. 2016]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alemtuzumab for multiple sclerosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Riera R, Porfírio GJ, Torloni MR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cochrane Database Syst Rev. 2016 Apr 15; 4:CD011203. Epub 2016 Apr 15.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/19052972" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Pharmacokinetics of alemtuzumab and the relevance in clinical practice.</a><span class="source">[Leuk Lymphoma. 2008]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Pharmacokinetics of alemtuzumab and the relevance in clinical practice.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Elter T, Molnar I, Kuhlmann J, Hallek M, Wendtner C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Leuk Lymphoma. 2008 Dec; 49(12):2256-62. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643537" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643537" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="&#10;                        HTOn&#10;                    "><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:04:55-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal106&amp;ncbi_phid=CE8D1A31046640E10000000003C30104&amp;ncbi_session=CE8D1A3104675551_0963SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548212%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548212&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548212/&amp;ncbi_pagename=Alemtuzumab - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D1A3104675551_0963SID /projects/books/PBooks@9.2 portal106 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>